

Himmelfarb Health Sciences Library, The George Washington University

Health Sciences Research Commons

Radiology Faculty Publications

Radiology

11-1-2021

ACR Appropriateness Criteria® Parathyroid Adenoma.

David Zander

Paul M Bunch

Bruno Policeni

Amy F Juliano

Denise Carneiro-Pla

See next page for additional authors

Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/smhs_rad_facpubs

 Part of the [Radiology Commons](#)

Authors

David Zander, Paul M Bunch, Bruno Policeni, Amy F Juliano, Denise Carneiro-Pla, Prachi Dubey, Maria K Gule-Monroe, Mari Hagiwara, Jenny K Hoang, Vikas Jain, Lawrence T Kim, Gul Moonis, Matthew S Parsons, Tanya J Rath, Carmen C Solórzano, Rathan M Subramaniam, M Reza Taheri, Kate DuChene Thoma, Andrew T Trout, Mark E Zafereo, and Amanda S Corey

ACR Appropriateness Criteria[®]

Parathyroid Adenoma

Expert Panel on Neurological Imaging: *David Zander, MD^a, Paul M. Bunch, MD^b, Bruno Policeni, MD, MBA^c, Amy F. Juliano, MD^d, Denise Carneiro-Pla, MD^e, Prachi Dubey, MBBS, MPH^f, Maria K. Gule-Monroe, MD^g, Mari Hagiwara, MD^h, Jenny K. Hoang, MBBS, MHS, MBAⁱ, Vikas Jain, MD^j, Lawrence T. Kim, MD^k, Gul Moonis, MD^l, Matthew S. Parsons, MD^m, Tanya J. Rath, MDⁿ, Carmen C. Solórzano, MD^o, Rathan M. Subramaniam, MD, PhD, MPH^p, M. Reza Taheri, MD, PhD^q, Kate DuChene Thoma, MD, MME^r, Andrew T. Trout, MD^s, Mark E. Zafereo Jr, MD^t, Amanda S. Corey, MD^u*

Abstract

Hyperparathyroidism is defined as excessive parathyroid hormone production. The diagnosis is made through biochemical testing, in which imaging has no role. However, imaging is appropriate for preoperative parathyroid gland localization with the intent of surgical cure. Imaging is particularly useful in the setting of primary hyperparathyroidism whereby accurate localization of a single parathyroid adenoma can facilitate minimally invasive parathyroidectomy. Imaging can also be useful to localize ectopic or supernumerary

^aChief, Head and Neck Radiology, University of Colorado Denver, Denver, Colorado.

^bResearch Author, Wake Forest School of Medicine, Winston Salem, North Carolina.

^cPanel Chair; and Director, Research and Academic Affairs, University of Iowa Hospitals and Clinics, Iowa City, Iowa.

^dPanel Vice-Chair, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts; and ACR Chair, NI-RADS Committee.

^eMedical University of South Carolina, Charleston, South Carolina; American Thyroid Association.

^fHouston Methodist Hospital, Houston, Texas.

^gMedical Director, Division of Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas.

^hNew York University Langone Medical Center, New York, New York; and Secretary, Eastern Neuroradiological Society.

ⁱJohns Hopkins Hospital, Baltimore, Maryland.

^jAssociate Radiology Residency Program Director, MetroHealth Medical Center, Cleveland, Ohio.

^kUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina; American College of Surgeons.

^lColumbia University Medical Center, New York, New York.

^mMallinckrodt Institute of Radiology, Saint Louis, Missouri.

ⁿDirector, Neuroradiology Division Education, Mayo Clinic Arizona, Phoenix, Arizona; and President, Eastern Neuroradiological Society.

^oVanderbilt University Medical Center, Nashville, Tennessee; Society of Surgical Oncology.

^pUniversity of Otago, Dunedin, Otepoti, New Zealand; and PET Center of Excellence, Society of Nuclear Medicine and Molecular Imaging.

^qGeorge Washington University Hospital, Washington, District of Columbia.

^rUniversity of Iowa Hospital, Iowa City, Iowa.

^sDirector, Radiology Clinical Research, Department of Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; JRCNMT, Board Member and Vice-Chair; and ACR representative.

^tAssociate Medical Director, Head & Neck Center, The University of Texas MD Anderson Cancer Center, Houston, Texas; American Academy of Otolaryngology-Head and Neck Surgery.

^uSpecialty Chair, Atlanta VA Health Care System and Emory University, Atlanta, Georgia.

Corresponding author: David A Zander, MD, Univ of Colorado Anschutz Medical Campus, Dept of Radiology, 12401 E 17th Ave, MS L954, Aurora, CO 80045; e-mail: David.zander@cuanschutz.edu.

The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply individual or society endorsement of the final document. Reprint requests to: publications@acr.org.

The authors state that they have no conflict of interest related to the material discussed in this article. Dr Rath is on a partnership track; and all other authors are non-partner/non-partnership track/employees.

The ACR Appropriateness Criteria documents are updated regularly. Please go to the ACR website at www.acr.org/ac to confirm that you are accessing the most current content.

Disclaimer: The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.

parathyroid glands and detail anatomy, which may impact surgery. This document summarizes the literature and provides imaging recommendations for hyperparathyroidism including primary hyperparathyroidism, recurrent or persistent primary hyperparathyroidism after parathyroid surgery, secondary hyperparathyroidism, and tertiary hyperparathyroidism. Recommendations include ultrasound, CT neck without and with contrast, and nuclear medicine parathyroid scans.

The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

Key Words: Appropriateness Criteria, Appropriate Use Criteria, AUC, Hyperparathyroidism, Parathyroid adenoma, Primary hyperparathyroidism, Recurrent hyperparathyroidism, Secondary hyperparathyroidism, Tertiary hyperparathyroidism

J Am Coll Radiol 2021;18:S406-S422. Copyright © 2021 American College of Radiology

ACR Appropriateness Criteria® Parathyroid Adenoma. [Variants 1 to 4](#) and [Tables 1 and 2](#).

Variant 1. Adult or child. Primary hyperparathyroidism. Initial imaging.		
Procedure	Appropriateness Category	Relative Radiation Level
US parathyroid	Usually Appropriate	○
Sestamibi scan and pertechnetate thyroid scan	Usually Appropriate	⊕⊕⊕
CT neck without and with IV contrast	Usually Appropriate	⊕⊕⊕
Sestamibi dual-phase scan neck	Usually Appropriate	⊕⊕⊕
Sestamibi dual-phase scan with SPECT or SPECT/CT neck	Usually Appropriate	⊕⊕⊕
Sestamibi scan and I-123 thyroid scan	Usually Appropriate	⊕⊕⊕
Sestamibi scan and I-123 thyroid scan with SPECT or SPECT/CT neck	Usually Appropriate	⊕⊕⊕
Sestamibi scan and pertechnetate thyroid scan with SPECT or SPECT/CT neck	Usually Appropriate	⊕⊕⊕
MRI neck with IV contrast	May Be Appropriate	○
MRI neck without and with IV contrast	May Be Appropriate	○
CT neck with IV contrast	May Be Appropriate	⊕⊕⊕
Venous sampling parathyroid	Usually Not Appropriate	Varies
MRI neck without IV contrast	Usually Not Appropriate	○
CT neck without IV contrast	Usually Not Appropriate	⊕⊕⊕

Variant 2. Adult or child. Primary hyperparathyroidism, recurrent or persistent after parathyroid surgery. Initial imaging.

Procedure	Appropriateness Category	Relative Radiation Level
US parathyroid	Usually Appropriate	0
Sestamibi scan and pertechnetate thyroid scan	Usually Appropriate	☼☼☼
CT neck without and with IV contrast	Usually Appropriate	☼☼☼
Sestamibi dual-phase scan neck	Usually Appropriate	☼☼☼
Sestamibi dual-phase scan with SPECT or SPECT/CT neck	Usually Appropriate	☼☼☼
Sestamibi scan and I-123 thyroid scan	Usually Appropriate	☼☼☼
Sestamibi scan and I-123 thyroid scan with SPECT or SPECT/CT neck	Usually Appropriate	☼☼☼
Sestamibi scan and pertechnetate thyroid scan with SPECT or SPECT/CT neck	Usually Appropriate	☼☼☼
Venous sampling parathyroid	May Be Appropriate	Varies
MRI neck with IV contrast	May Be Appropriate	0
MRI neck without and with IV contrast	May Be Appropriate	0
CT neck with IV contrast	May Be Appropriate	☼☼☼
MRI neck without IV contrast	Usually Not Appropriate	0
CT neck without IV contrast	Usually Not Appropriate	☼☼☼

Variant 3. Adult or child. Secondary hyperparathyroidism. Initial imaging.

Procedure	Appropriateness Category	Relative Radiation Level
US parathyroid	Usually Appropriate	0
CT neck without and with IV contrast	Usually Appropriate	☼☼☼
Sestamibi dual-phase scan neck	Usually Appropriate	☼☼☼
Sestamibi dual-phase scan with SPECT or SPECT/CT neck	Usually Appropriate	☼☼☼
Sestamibi scan and I-123 thyroid scan with SPECT or SPECT/CT neck	Usually Appropriate	☼☼☼
Sestamibi scan and pertechnetate thyroid scan with SPECT or SPECT/CT neck	Usually Appropriate	☼☼☼
Sestamibi scan and pertechnetate thyroid scan	May Be Appropriate (Disagreement)	☼☼☼
MRI neck with IV contrast	May Be Appropriate	0
MRI neck without and with IV contrast	May Be Appropriate	0
CT neck with IV contrast	May Be Appropriate	☼☼☼
Sestamibi scan and I-123 thyroid scan	May Be Appropriate (Disagreement)	☼☼☼
Venous sampling parathyroid	Usually Not Appropriate	Varies
MRI neck without IV contrast	Usually Not Appropriate	0
CT neck without IV contrast	Usually Not Appropriate	☼☼☼

Variant 4. Adult or child. Tertiary hyperparathyroidism. Initial imaging.

Procedure	Appropriateness Category	Relative Radiation Level
US parathyroid	Usually Appropriate	○
Sestamibi scan and pertechnetate thyroid scan	Usually Appropriate	⊗⊗⊗
CT neck without and with IV contrast	Usually Appropriate	⊗⊗⊗
Sestamibi dual-phase scan neck	Usually Appropriate	⊗⊗⊗
Sestamibi dual-phase scan with SPECT or SPECT/CT neck	Usually Appropriate	⊗⊗⊗
Sestamibi scan and I-123 thyroid scan with SPECT or SPECT/CT neck	Usually Appropriate	⊗⊗⊗
Sestamibi scan and pertechnetate thyroid scan with SPECT or SPECT/CT neck	Usually Appropriate	⊗⊗⊗
MRI neck with IV contrast	May Be Appropriate	○
MRI neck without and with IV contrast	May Be Appropriate	○
CT neck with IV contrast	May Be Appropriate	⊗⊗⊗
Sestamibi scan and I-123 thyroid scan	May Be Appropriate (Disagreement)	⊗⊗⊗
Venous sampling parathyroid	Usually Not Appropriate	Varies
MRI neck without IV contrast	Usually Not Appropriate	○
CT neck without IV contrast	Usually Not Appropriate	⊗⊗⊗

Table 1. Appropriateness category names and definitions

Appropriateness Category Name	Appropriateness Rating	Appropriateness Category Definition
Usually Appropriate	7, 8, or 9	The imaging procedure or treatment is indicated in the specified clinical scenarios at a favorable risk-benefit ratio for patients.
May Be Appropriate	4, 5, or 6	The imaging procedure or treatment may be indicated in the specified clinical scenarios as an alternative to imaging procedures or treatments with a more favorable risk-benefit ratio, or the risk-benefit ratio for patients is equivocal.
May Be Appropriate (Disagreement)	5	The individual ratings are too dispersed from the panel median. The different label provides transparency regarding the panel's recommendation. "May be appropriate" is the rating category and a rating of 5 is assigned.
Usually Not Appropriate	1, 2, or 3	The imaging procedure or treatment is unlikely to be indicated in the specified clinical scenarios, or the risk-benefit ratio for patients is likely to be unfavorable.

Table 2. Relative radiation level designations

RRL	Adult Effective Dose Estimate Range (mSv)	Pediatric Effective Dose Estimate Range (mSv)
0	0	0
⊕	<0.1	<0.03
⊕⊕	0.1-1	0.03-0.3
⊕⊕⊕	1-10	0.3-3
⊕⊕⊕⊕	10-30	3-10
⊕⊕⊕⊕⊕	30-100	10-30

Note: Relative radiation level (RRL) assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (eg, region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as “varies.”

SUMMARY OF LITERATURE REVIEW

Introduction/Background

Hyperparathyroidism is defined as excessive parathyroid hormone (PTH) production. The most common form, primary hyperparathyroidism (PHPT), occurs when ≥ 1 parathyroid glands autonomously overproduce PTH, typically resulting in hypercalcemia [1]. PHPT is diagnosed by biochemical testing, specifically serum calcium and serum PTH. Usually due to a single parathyroid adenoma (80%), PHPT can also occur from multiple adenomas, parathyroid hyperplasia, or, rarely, parathyroid carcinoma (<1%). Multigland disease (MGD), defined as multiple adenomas or multiple gland hyperplasia, affects approximately 15% to 20% of patients with PHPT [1,2]. PHPT is more common in women, with an incidence of 66 per 100,000 person-years, and 25 per 100,000 person-years in men; the prevalence appears to be increasing significantly [3]. Most cases are sporadic, although hereditary causes exist, including multiple endocrine neoplasia types 1 and 2A as well as familial hyperparathyroidism. In countries where biochemical screening is routine, such as the United States, Canada, and most of Europe, PHPT predominately presents as an asymptomatic disorder. Conversely, in countries where routine biochemical screening is not commonplace, such as China or India, PHPT predominately presents with symptoms related to target organ involvement including: bone demineralization, fractures, nephrolithiasis, nephrocalcinosis, muscle weakness, or neurocognitive disorders [1]. Treatment of PHPT is surgical excision of the abnormally functioning parathyroid tissue and is typically indicated even when asymptomatic, given potential negative effects of long-term hypercalcemia [1,2].

There are 2 accepted curative operative strategies for PHPT: bilateral neck exploration (BNE) and minimally invasive parathyroidectomy (MIP). BNE refers to a bilateral

operation in which all parathyroid glands are identified and examined by the surgeon, who resects the diseased glands. MIP is defined variably in the literature, for this document, MIP refers to a unilateral operation utilizing limited dissection for targeted removal of only the affected gland. MIP is therefore less invasive than BNE. BNE has traditionally been the standard surgical method of parathyroidectomy and remains the necessary method in cases of discordant or nonlocalizing preoperative imaging or when there is high suspicion for MGD [2]. However, because most patients with PHPT have a single adenoma [2], directed MIP is often performed as it conveys the benefits of shorter operating times, faster recovery, and decreased perioperative costs [4-8]. MIP requires confident and precise preoperative localization of a single parathyroid adenoma to guide the surgical approach; intraoperative PTH monitoring is used to confirm removal of the hyperfunctioning gland [2,9]. Therefore, the role of imaging in PHPT is to localize the abnormally functioning gland or glands with high accuracy and high confidence to facilitate targeted curative surgery. Importantly, imaging has no utility in confirming or excluding the diagnosis of PHPT [2,8].

Persistent PHPT is defined as failure to achieve normocalcemia within 6 months of initial parathyroidectomy, whereas recurrent PHPT is defined as hypercalcemia occurring after a normocalcemic interval of 6 months or more after parathyroidectomy [2,10]. Parathyroid reoperations are surgically challenging, with lower cure rates than first-time surgery and higher complication rates. As such, recent international guidelines state that preoperative imaging is essential in the reoperative setting to localize a target parathyroid lesion (or lesions) and to identify postoperative changes from previous parathyroid explorations that can impact a subsequent surgery [10].

Secondary hyperparathyroidism (SHPT) is a failure of calcium homeostasis whereby increased PTH production in response to hypocalcemia (and/or hyperphosphatemia) is unable to correct plasma calcium because of organ failure or reduced calcium availability. This is most commonly due to chronic kidney disease but can also be a result of malabsorption or vitamin D deficiency, among other causes [11]. Rarely, tertiary hyperparathyroidism (THPT) can occur in patients with long-standing SHPT and is characterized by a lack of PTH suppression despite rising serum calcium levels, manifesting as hypercalcemic hyperparathyroidism. This is most commonly encountered following kidney transplantation in patients with long-standing chronic kidney disease [11]. Surgical excision is recommended for medically refractory cases of SHPT and THPT. As these are typically disorders of MGD (ie, parathyroid hyperplasia), the goal of imaging is to identify all eutopic and potential ectopic or supernumerary glands in an attempt to guide the surgical approach [10,12-14].

Initial Imaging Definition

Initial imaging is defined as imaging at the beginning of the care episode for the medical condition defined by the variant. More than one procedure can be considered usually appropriate in the initial imaging evaluation when:

- There are procedures that are equivalent alternatives (ie, only one procedure will be ordered to provide the clinical information to effectively manage the patient's care)

OR

- There are complementary procedures (ie, more than one procedure is ordered as a set or simultaneously in which each procedure provides unique clinical information to effectively manage the patient's care).

There is no universally accepted algorithm for parathyroid imaging. As detailed in the following variants, there is much variability in the reported sensitivities for imaging modalities, with no single technique shown to be clearly superior in localizing parathyroid lesions in all patients. The selection of an initial imaging study should be made with consideration for surgeon and radiologist preference, regional expertise, and characteristics unique to each patient's presentation (eg, suspicion for MGD, underlying hereditary cause, concomitant thyroid disease, etc). Multiple imaging modalities may be utilized in combination during the initial imaging evaluation in an attempt to maximize the accuracy and confidence of parathyroid localization via concordant imaging results [2,8,10,15]. This is supported by various studies in the literature showing improved sensitivity and positive predictive value (PPV) in parathyroid

lesion localization with a combination of examinations over each examination in isolation [12,16-25].

Special Imaging Considerations

For the purposes of parathyroid imaging, CT neck without and with intravenous (IV) contrast is understood to represent a "4-D parathyroid CT." Originally described in 2006 [26], this multiphase technique leverages the unique perfusion characteristics of parathyroid adenomas to differentiate them from mimics such as exophytic thyroid nodules and lymph nodes. Variations on the original 4-phase 4-D parathyroid CT technique have since been described, including 2- [27] and 3-phase [28-33] protocols. The optimal number of postcontrast phases is undetermined; however, the most commonly performed method consists of 3 phases: noncontrast, arterial, and venous [34].

DISCUSSION OF PROCEDURES BY VARIANT

Variant 1: Adult or child. Primary hyperparathyroidism. Initial imaging

All patients undergoing imaging in the setting of PHPT should have biochemically proven disease, as imaging has no role in confirming or excluding the diagnosis [2]. As such, assessing the imaging test specificity and negative predictive value is not clinically relevant. Rather, the role of initial imaging in PHPT is to aid in selecting appropriate patients for MIP by accurately identifying and localizing a single parathyroid adenoma; accordingly, these criteria focus on imaging test sensitivity and PPV. Patients with negative or inconclusive imaging results typically remain surgical candidates but will likely require BNE; inconclusive findings on imaging should not preclude surgical referral [2].

Multiple imaging modalities may be utilized in combination during the initial imaging evaluation of PHPT in an attempt to maximize the accuracy and confidence of parathyroid localization via concordant imaging results [2,8,15]. This is supported by multiple studies in the literature showing improved sensitivity and PPV in parathyroid lesion localization with a combination of examinations over each examination in isolation [16-23,25].

CT Neck. Neck CT for preoperative localization of PHPT is most commonly performed without and with IV contrast (4-D parathyroid CT) [34]. As such, most published data relate to the performance of CT neck without and with IV contrast; however, there are also some data on the performance of CT neck with IV contrast. There is no relevant literature regarding the use of CT neck without IV contrast in the evaluation of PHPT.

As the initial imaging study, retrospective studies report the overall sensitivity of CT neck without and with IV contrast to range between 62% and 88% [35,36] and the overall PPV to range between 84% and 90% [32,37]. The largest retrospective study (400 patients) reports an overall sensitivity of 79% and PPV of 90% [32]. For single-gland disease, reported sensitivities and PPVs range from 92% to 94% [30,38] and 88% to 92% [38,39], respectively. For MGD, reported sensitivities and PPVs range from 43% to 67% [39,40] and 89% to 100%, respectively [32,39].

A data-driven rationale for the noncontrast CT phase has been provided (eg, differentiation of parathyroid from thyroid tissue): 22% of parathyroid lesions have an enhancement pattern similar to thyroid on arterial and venous phases and therefore may be missed if the non-contrast phase were excluded [30]. However, a few retrospective reports suggest that eliminating the noncontrast CT phase may not adversely affect test performance [41-43]. The largest retrospective study (278 patients) of CT neck with IV contrast (without the noncontrast phase) reports sensitivity of 55% and PPV of 57% among patients with single-gland disease, and sensitivity of 23% and PPV of 19% among patients with MGD [44].

Several studies have directly compared the performance of neck CT without and with IV contrast to ultrasound (US) and to nuclear medicine scans within the same patient population. Most of these studies found the performance of neck CT without and with IV contrast to be superior [29,31,38,40]; however, a prospective study of 91 patients found neck CT without and with IV contrast (58% sensitivity, 88% PPV) to be inferior to dual isotope (sestamibi and I-123) pinhole subtraction scintigraphy (93% sensitivity, 98% PPV) [45].

MRI Neck. MRI neck is an emerging technique for PHPT preoperative localization and may be performed without IV contrast, with IV contrast, or without and with IV contrast. Most studies evaluating the performance of MRI neck for preoperative localization in the setting of PHPT are retrospective and include fewer than 50 patients.

As the initial imaging study, the sensitivity of MRI neck without and with IV contrast performed at 1.5T has been reported to be between 64% and 79% [46-48]. In 2 prospective studies performed at 3.0T, the sensitivity of MRI neck without and with IV contrast ranged between 64% and 98%, and the PPV ranged between 67% and 95% [49,50]. A third prospective study of MRI without and with IV contrast performed at 3.0T reported accurate localization of parathyroid adenomas in 92% (34/37) of patients with single-gland disease and 74% (35/47) of patients with MGD [51]. For MRI without IV contrast, the

reported sensitivity was 67% at 1.5T [52]. There is no relevant literature regarding the use of 3.0T MRI without IV contrast in the initial imaging evaluation of PHPT.

Sestamibi Dual-Phase Scan Neck. Dual-phase Tc-99m sestamibi planar parathyroid scintigraphy is an accepted and traditionally widely utilized method for parathyroid adenoma localization in PHPT. The sensitivity of this method (typically reported as localization to the correct quadrant or to an ectopic location) varies widely in the literature, ranging from 41% to 96% [45,52-63]. A larger retrospective study of 180 patients reported a sensitivity of 79% [58]. A systematic review of 11 studies reported a pooled sensitivity of 76% [17]. Some variability in these results may arise from varied technical parameters of these scans (eg, timing of early and delayed scans, use of pinhole versus parallel collimators, addition of oblique acquisitions, etc).

There is no clear consensus regarding the superiority between sestamibi dual-phase and dual-tracer subtraction planar imaging. One recent study of 63 patients showed greater sensitivity with dual-phase sestamibi (79%) over both dual-tracer (sestamibi and pertechnetate) (69%) and a combined dual-tracer/dual-phase technique (65%) [59]. However, other studies report similar or improved sensitivity of dual-tracer methods (either pertechnetate or I-123, plus sestamibi) over dual-phase sestamibi when utilizing a planar technique [45,54,64,65]. There is a growing consensus that the addition of single-photon emission CT (SPECT) without or with a coregistered CT (SPECT/CT) improves localization of parathyroid adenomas over a planar dual-phase sestamibi method [59,61,62].

The sensitivity of sestamibi imaging is decreased in the setting of MGD [55,58], concomitant nodular thyroid disease [56,66], small adenomas [53], and mild hypercalcemia [58].

Literature regarding the pediatric population is limited. A retrospective review of 29 patients reported that sestamibi was useful only in older children with a single adenoma in the setting of sporadic PHPT, and added minimal additional information compared with US, with otherwise no utility for sestamibi in neonates or familial PHPT [67].

Sestamibi Dual-Phase Scan With SPECT or SPECT/CT Neck. The addition of SPECT or SPECT/CT to a dual-phase sestamibi scan is more commonly utilized than planar imaging alone. Although there are a number of variations in the timing of the SPECT or SPECT/CT acquisition (ie, early, delayed, or both), it is generally accepted that the improved contrast resolution of SPECT or SPECT/CT over planar imaging provides more precise anatomic localization of parathyroid adenomas [68,69].

Reported sensitivities of sestamibi dual-phase scan with SPECT or SPECT/CT range from 67% to 86%.

- Thomas et al: In a study of patients with parathyroid adenomas and parathyroid hyperplasia, direct comparison of dual-phase sestamibi planar imaging to dual-phase sestamibi with SPECT showed improved sensitivities from 42% to 67%, respectively; this includes detection of parathyroid hyperplasia by SPECT, which was missed by planar imaging [61].
- Cheung et al: A meta-analysis of 7 studies found a pooled sensitivity of 79% and a pooled PPV of 91% for dual-phase sestamibi with SPECT [70].
- Wong et al: A meta-analysis of 24 studies found a pooled sensitivity of 86% for dual-phase sestamibi with SPECT/CT compared with 74% for sestamibi with SPECT and 70% for sestamibi planar alone [62].
- Yeh et al: A study of 400 patients reported a sensitivity of 58% and PPV of 96% for sestamibi with SPECT/CT. A combined method of sestamibi with SPECT/CT plus 4-D parathyroid CT yielded a sensitivity of 80%, which was not substantially different than 4-D parathyroid CT alone at 79% [32].

The sensitivity of dual-phase sestamibi with SPECT or SPECT/CT is decreased by MGD, uptake masked by retained radionuclide in adjacent thyroid or submandibular gland tissue, and smaller size of the adenoma (within these subsets, sensitivity ranges from 24% to 66%) [71-73].

Sestamibi Scan and I-123 Thyroid Scan. Subtraction scintigraphy of parathyroid glands using a combination of sestamibi and I-123 sodium iodide is a commonly utilized alternative or adjunct to the dual-phase sestamibi technique. The 2009 European Association of Nuclear Medicine parathyroid guidelines expressed a preference for the dual-tracer sestamibi and I-123 technique, citing improved sensitivity for MGD and improved likelihood of distinguishing sestamibi-avid thyroid nodules from parathyroid lesions [15]. A major technical advantage of using I-123 for a subtraction technique is that thyroid and parathyroid images can be acquired simultaneously in a dual-energy window.

Reported sensitivity for dual-tracer sestamibi and I-123 subtraction scintigraphy ranges from 75% to 94% [54,74-76], including a retrospective review of 2,681 patients revealing a sensitivity of 87% and PPV of 92% [77]. The latter study showed that negative or inconclusive results had a higher association with MGD and lower serum calcium levels.

There is no clear consensus regarding the superiority between dual-tracer subtraction and sestamibi dual-phase planar imaging. One recent study of 63 patients showed

greater sensitivity with dual-phase sestamibi (79%) over both dual-tracer (sestamibi and pertechnetate) (69%) and a combined dual-tracer/dual-phase (65%) technique [59]. However, other studies report similar or improved sensitivity of dual-tracer methods (either pertechnetate or I-123, plus sestamibi) over dual-phase sestamibi when utilizing a planar technique [45,54,64,65].

Sestamibi Scan and I-123 Thyroid Scan With SPECT or SPECT/CT Neck. Although there are a number of variations in the timing of the SPECT or SPECT/CT acquisition (ie, early, delayed, or both), it is generally accepted that the improved contrast resolution of SPECT or SPECT/CT over planar imaging provides more precise anatomic localization of parathyroid adenomas [68,69]. However, there are conflicting data in the literature as to what extent the addition of SPECT or SPECT/CT changes the sensitivity of the examination. For example, Bhatt et al [74] evaluated a pinhole protocol, SPECT/CT alone, and a combination of pinhole/SPECT/CT, revealing sensitivities of 88%, 69%, and 81%, respectively. Other studies have shown superior performance of the combined sestamibi/I-123 plus SPECT/CT protocol with sensitivities ranging from 86% to 95% and PPV from 86% to 100% [45,75,78,79].

The sensitivity and PPV of a sestamibi/I-123 subtraction technique are least negatively impacted by concomitant thyroid disease when SPECT/CT is included in the protocol [75].

Sestamibi Scan and Pertechnetate Thyroid Scan. Subtraction scintigraphy of parathyroid glands using a combination of sestamibi and Tc-99m pertechnetate is a commonly utilized alternative or adjunct to the dual-phase sestamibi technique. Unlike the dual-tracer method with I-123, the pertechnetate method requires 2 separate acquisitions, which prolongs the overall examination time. Although techniques based solely on planar imaging have largely been supplanted by methods with SPECT or SPECT/CT, there are some noteworthy applications of a planar sestamibi and pertechnetate subtraction in recent literature with reported sensitivities ranging from 69% to 79% [59,80]. A meta-analysis including 5 studies utilizing a dual-tracer technique reported sensitivities ranging from 47% to 87%; however, it is unclear which studies relied purely on a subtracted dual-tracer (sestamibi and pertechnetate) planar method and which were performed in combination with a dual-phase sestamibi scan [17]. In a study of 116 patients with PHPT, the addition of pertechnetate subtraction to a dual-phase sestamibi scan increased reader confidence in adenoma localization and changed the final interpretation in 15% of patients from the dual-phase study [81].

MGD decreases the sensitivity of the subtraction sestamibi and pertechnetate scan from 71% to 64% [82].

There is no clear consensus regarding the superiority between dual-tracer subtraction and sestamibi dual-phase planar imaging. One recent study of 63 patients showed greater sensitivity with dual-phase sestamibi (79%) over both dual-tracer (sestamibi and pertechnetate) (69%) and a combined dual-tracer/dual-phase technique (65%) [59]. However, other studies report similar or improved sensitivity of dual-tracer methods (either pertechnetate or I-123, plus sestamibi) over dual-phase sestamibi when utilizing a planar technique [45,54,64,65].

Sestamibi Scan and Pertechnetate Thyroid Scan With SPECT or SPECT/CT Neck. Although there are a number of variations in the timing of the SPECT or SPECT/CT acquisition (ie, early, delayed, or both), it is generally accepted that the greater contrast resolution of SPECT or SPECT/CT over planar imaging provides more precise anatomic localization of parathyroid adenomas [68,69]. The addition of a pertechnetate thyroid scan may further improve localization: in a study of 268 patients, planar pertechnetate subtraction in combination with a dual-phase sestamibi scan with SPECT/CT outperformed the dual-phase sestamibi SPECT/CT alone, increasing sensitivity to 93% and PPV to 96% compared with 88% and 92%, respectively [83].

In patients with concomitant thyroid disease, the addition of CT to a dual-tracer sestamibi and pertechnetate SPECT scan increases sensitivity from 80% to 94% [84].

US Parathyroid. US of the parathyroid glands is widely utilized as the initial imaging study in PHPT. Both the American Head and Neck Society Endocrine Surgery Section and the American Association of Endocrine Surgeons deem US to be the preferred initial localization study in patients with PHPT, noting the advantage of concomitant thyroid evaluation [2,8]. A 2012 meta-analysis of 19 studies evaluating US in patients with PHPT revealed a pooled sensitivity of 76% and PPV of 93% [70]. A subsequent 2017 meta-analysis of 12 studies (with few studies also included from the 2012 meta-analysis) revealed a pooled sensitivity of 80% [85]. However, the range of sensitivities reported in the literature varies widely. For example, a study of 604 patients comparing US, scintigraphy, and 4-D CT reported a sensitivity of 59% for US [31], with other smaller studies reporting US sensitivities ranging from 44% to 97% [18,20,58,86-90].

Nonlocalizable adenomas by US are most often due to ectopic or far posterior location, MGD, small adenoma size, and concomitant thyroid disease [58,86,91].

The literature in the pediatric population is limited. In a retrospective review of 29 patients, Alagaratnam et al [67] reported that US in 2 neonates resulted in false-negatives; sensitivity improved in older children to 93%. In a separate study of 16 children, sensitivity of US was 60% [7].

Venous Sampling Parathyroid. Parathyroid glands tend to drain ipsilaterally and inferiorly relative to their anatomic location. As such, sampling of PTH levels during selective transvenous catheterization of multiple neck and mediastinal veins can be used to infer the laterality and regional location of parathyroid lesions [8,92,93]. Direct differential jugular venous sampling of PTH to infer laterality of an adenoma in patients with PHPT has also been described in the literature but is beyond the scope of this document [94,95]. Because of its invasive technique, selective parathyroid venous sampling is typically reserved for reoperative surgical candidates with recurrent or persistent PHPT after noninvasive examinations (eg, US, sestamibi, CT, etc) yield nonlocalizing, equivocal, or discordant results [96]. Otherwise, there are limited data regarding the use of selective venous sampling for parathyroid localization as the initial examination for PHPT in the surgically naïve patient. Hader et al [92] in a study of 23 patients from Germany underwent parathyroidectomy for hyperparathyroidism, 8 of which as their initial surgery, and results of selective parathyroid venous sampling were retrospectively reviewed. Across the entire cohort, the reported sensitivity was 94% and PPV was 89%.

Variant 2: Adult or child. Primary hyperparathyroidism, recurrent or persistent after parathyroid surgery. Initial imaging

All patients undergoing imaging in the setting of recurrent or persistent PHPT should have biochemically proven disease, as imaging has no role in confirming or excluding the diagnosis [2,10]. As such, assessing the imaging test specificity and negative predictive value is not clinically relevant. Rather, the role of initial imaging in recurrent or persistent PHPT is to accurately identify and localize a parathyroid lesion (or lesions) and identify postoperative changes from previous parathyroid explorations, which can impact a subsequent surgery. Accordingly, these criteria focus on imaging test sensitivity and PPV.

Multiple imaging modalities may be utilized in combination during the initial imaging evaluation of recurrent or persistent PHPT after prior surgery in an attempt to maximize the accuracy and confidence of parathyroid localization via concordant imaging results [10,15].

CT Neck. Neck CT in the evaluation of recurrent or persistent PHPT after prior surgery is most commonly

performed without and with IV contrast (4-D parathyroid CT) [34], which is reflected in the published data regarding the performance of neck CT for parathyroid localization in the setting of prior failed surgery. There is no literature regarding the use of CT neck with IV contrast specifically limited to patients with recurrent or persistent PHPT. Additionally, there is no relevant literature regarding the use of CT neck without IV contrast in the evaluation of PHPT.

In the setting of recurrent or persistent PHPT, retrospective studies report the sensitivity of CT neck without and with IV contrast to range between 50% and 91% and the PPV to range between 69% and 100% [29,36,40,97].

MRI Neck. Neck MRI is an emerging technique in the evaluation of recurrent or persistent PHPT after prior surgery. There are limited data regarding the use of MRI neck without and with IV contrast in the setting of prior surgery:

- Aschenbach et al: 30 patients from Germany underwent reoperative parathyroidectomy for PHPT, and results of MRI performed prior to reoperation were retrospectively reviewed. Using only conventional MRI sequences (without and with IV contrast), the sensitivity was 63%, and the PPV was 100%. With the addition of dynamic sequences, the sensitivity was 93%, and the PPV was 100% [98].
- Kluijfhout et al: 84 patients from California underwent reoperative parathyroidectomy for persistent PHPT, and results of MRI performed prior to reoperation were retrospectively reviewed. The sensitivity of MRI neck without and with IV contrast was 82%, and the PPV was 85%. The sensitivity and PPV of dynamic sequences were both 90% [48].

There is no relevant literature regarding the use of MRI without IV contrast in the evaluation of recurrent or persistent PHPT.

Sestamibi Dual-Phase Scan Neck. There is no relevant literature regarding the use of planar sestamibi dual-phase scans in the evaluation of recurrent or persistent PHPT after prior surgery.

Sestamibi Dual-Phase Scan With SPECT or SPECT/CT Neck. There are limited data regarding the use of sestamibi dual-phase scans with SPECT or SPECT/CT in the setting of prior surgery:

- Kluijfhout et al: 84 patients from California underwent reoperative parathyroidectomy for persistent PHPT, and results of sestamibi scans with SPECT/CT performed prior to reoperation were retrospectively reviewed. The reported sensitivity was 74%, and the PPV was 86% [48].

- Witteveen et al: 19 patients from The Netherlands underwent reoperative parathyroidectomy for persistent PHPT. Results of sestamibi scans with SPECT performed prior to reoperation were retrospectively reviewed and compared with a 23-patient cohort undergoing the same preoperative imaging for surgically naïve sporadic PHPT. For patients with persistent PHPT, the sensitivity for localizing parathyroid glands on a per-lesion basis was 33% as compared with 61% for the cohort imaged prior to their initial surgery [99].

Sestamibi Scan and I-123 Thyroid Scan. There is no relevant literature regarding the use of planar sestamibi and I-123 scans in the evaluation of recurrent or persistent PHPT after prior surgery.

Sestamibi Scan and I-123 Thyroid Scan With SPECT or SPECT/CT Neck. There are limited data regarding the use of sestamibi and I-123 scans with SPECT or SPECT/CT in the setting of recurrent or persistent PHPT after prior surgery:

- Shin et al: 176 patients from Ohio underwent reoperative parathyroidectomy for recurrent or persistent hyperparathyroidism, including patients with PHPT, SHPT, and THPT. Results of sestamibi and I-123 scans with SPECT (103 patients) and sestamibi and I-123 scans with SPECT/CT (73 patients) performed prior to reoperation were retrospectively reviewed. Reported sensitivities were 74% and 86%, respectively [100].

Sestamibi Scan and Pertechnetate Thyroid Scan. There is no relevant literature regarding the use of planar sestamibi and pertechnetate scans in the evaluation of recurrent or persistent PHPT after prior surgery.

Sestamibi Scan and Pertechnetate Thyroid Scan With SPECT or SPECT/CT Neck. There is no relevant literature regarding the use of sestamibi and pertechnetate scans with SPECT or SPECT/CT in the evaluation of recurrent or persistent PHPT after prior surgery.

US Parathyroid. A 2017 joint consensus statement of the American Head and Neck Society and the British Association of Endocrine and Thyroid Surgeons recommends US as a first-line imaging examination in the reoperative setting, citing the added advantage of revealing nodular thyroid disease, lymphadenopathy, and postoperative changes from the previous parathyroid exploration [10]. Otherwise, there are limited data within the last 10 years regarding the use of US in the setting of recurrent or persistent hyperparathyroidism after prior surgery:

- Hamidi et al: 58 patients from Massachusetts underwent reoperative parathyroidectomy for recurrent or persistent PHPT and results of US performed prior to reoperation were retrospectively reviewed. An examination was considered a true-positive if it identified the correct laterality (compared to quadrant or region). The reported sensitivity on a per-lesion basis (62 lesions) was 46% [101].
- Kluijfhout et al: 84 patients from California underwent reoperative parathyroidectomy for persistent PHPT, and the results of US performed prior to reoperation were retrospectively reviewed. The reported sensitivity was 54%, and the PPV was 71% [48].
- Shin et al: 176 patients from Ohio underwent reoperative parathyroidectomy for recurrent or persistent hyperparathyroidism, including patients with PHPT, SHPT, and THPT. Results of US performed prior to reoperation were retrospectively reviewed, with reported sensitivity of 69% [100].

Venous Sampling Parathyroid. Parathyroid glands tend to drain ipsilaterally and inferiorly relative to their anatomic location. As such, sampling of PTH levels during selective transvenous catheterization of multiple neck and mediastinal veins can be used to infer the laterality and regional location of parathyroid lesions [8,92,93]. Because of its invasive technique, selective parathyroid venous sampling is typically reserved for reoperative surgical candidates with recurrent or persistent PHPT after noninvasive examinations (eg, US, sestamibi, CT, etc) yield nonlocalizing, equivocal, or discordant results [96,102].

Although parathyroid venous sampling has been in use since the 1990s [102], there are few pertinent studies within the last 10 years, and nearly all evaluate patients who have had prior nonlocalizing examinations, as this is the subset of patients for whom this examination is typically reserved. These studies are retrospective and each evaluated fewer than 40 patients, reporting sensitivities ranging from 40% to 93% [92,93,97,103-105].

There is a potential for false regionalization and/or lateralization of parathyroid lesions due to congenitally variant venous anatomy or alteration of regional venous drainage secondary to previous surgical interventions [93]. As with many invasive vascular procedures, venous sampling is potentially associated with serious but uncommon complications [10].

Variant 3: Adult or child. Secondary hyperparathyroidism. Initial imaging

All patients undergoing imaging in the setting of SHPT should have biochemically proven disease, as imaging has no role in confirming or excluding the diagnosis [11]. As such, assessing the imaging test specificity and negative predictive value is not

clinically relevant. Rather, as SHPT is typically a disorder of MGD and is therefore treated with BNE, the role of initial imaging is to accurately identify all eutopic and potential ectopic or supernumerary glands in an attempt to decrease surgical failure rates [12-14]; accordingly, these criteria focus on imaging test sensitivity and PPV.

It is possible that multiple imaging modalities may be utilized in combination during the initial imaging evaluation of SHPT in an attempt to maximize the accuracy and confidence of parathyroid localization via concordant imaging results. This is supported by limited literature specific to SHPT [12] and otherwise inferred from data regarding PHPT [16-23] showing improved sensitivity and PPV in parathyroid lesion localization with a combination of examinations over each examination in isolation.

CT Neck. There are limited data regarding the use of CT neck for localization in SHPT:

- Lee et al: 109 patients from Korea underwent parathyroidectomy for refractory SHPT, and results of preoperative localization studies were retrospectively reviewed. The reported sensitivity of CT neck was 85%, although details related to the CT acquisition (ie, without IV contrast, with IV contrast, or without and with IV contrast) are not provided; furthermore, the overall incidence of reported ectopic glands was much lower than typical at 1%, with all ectopic glands missed by CT [106].
- Hiramitsu et al: 291 patients from Japan underwent parathyroidectomy for SHPT, and results of preoperative localization studies were retrospectively reviewed. The reported sensitivity of CT neck was 60%, and the PPV was 100%. Details related to the CT acquisition are not provided [107].

MRI Neck. There is no relevant literature regarding the use of MRI neck performed without IV contrast, with IV contrast, or without and with IV contrast in the evaluation of SHPT.

Sestamibi Dual-Phase Scan Neck. There are limited data regarding the use of planar sestamibi dual-phase scans in the evaluation of SHPT:

- Vulpio et al: 21 patients from Italy underwent parathyroidectomy for SHPT, and the results of preoperative sestamibi scans were retrospectively reviewed. The reported sensitivity on a per-lesion basis was 62% [12].

Sestamibi Dual-Phase Scan With SPECT or SPECT/CT Neck. There are limited data regarding the use of sestamibi dual-phase scans with SPECT or SPECT/CT in the evaluation of SHPT:

- Yang et al: 80 patients from China with SHPT on hemodialysis underwent parathyroidectomy and results of preoperative sestamibi scans with SPECT/CT were retrospectively reviewed. The reported sensitivity was 85% on a per-patient basis [108].
- Li et al: 50 patients from China with SHPT underwent parathyroidectomy and results of preoperative sestamibi scans with SPECT/CT were retrospectively reviewed. The reported sensitivity was 59% on a per-lesion basis (out of 183 hyperplastic parathyroid glands) [109].
- Karipineni et al: This is the largest and most comprehensive study, a retrospective review of 2,975 patients from Maryland from 2004 to 2015. The aim of the study was to evaluate whether preoperative imaging could reliably identify ectopic glands in patients expected to have MGD. As such, the study was not limited to patients with SHPT but also included patients with THPT, lithium-induced PHPT, and PHPT due to multiple endocrine neoplasia; patients with SHPT comprised 55% of the cohort. On a per-lesion basis, the reported sensitivity of sestamibi dual-phase scans with SPECT in detecting ectopic glands was 29% [110].

Sestamibi Scan and I-123 Thyroid Scan. There is no relevant literature regarding the use of planar sestamibi scan and I-123 thyroid scan in the evaluation of SHPT.

Sestamibi Scan and I-123 Thyroid Scan With SPECT or SPECT/CT Neck. There are limited data regarding the use of sestamibi scan and I-123 thyroid scan with SPECT or SPECT/CT in the evaluation of SHPT:

- Alkhalili et al: 103 patients from the United States with either SHPT or THPT underwent parathyroidectomy and results of preoperative localization were retrospectively reviewed. The reported sensitivity for ectopic glands on a per-lesion basis by sestamibi and I-123 scan with SPECT was 36% [14].

Sestamibi Scan and Pertechnetate Thyroid Scan. There is no relevant literature regarding the use of planar sestamibi scan and pertechnetate thyroid scan in the evaluation of SHPT.

Sestamibi Scan and Pertechnetate Thyroid Scan With SPECT or SPECT/CT Neck. There is no relevant literature regarding the use of sestamibi scan and pertechnetate thyroid scan with SPECT or SPECT/CT in the evaluation of SHPT.

US Parathyroid. When utilized as an initial imaging study in SHPT, US conveys additional benefits of concomitant evaluation of the thyroid gland. Studies evaluating the use of US in patients with SHPT vary in their design. Those

studies evaluating the sensitivity of US on a per-lesion basis, inclusive of both eutopic and ectopic locations, report sensitivities ranging from 46% to 94% [12,85,111,112]. Although localization of eutopic glands is useful, the identification and localization of ectopic and supernumerary glands is paramount to decreasing failure rates of BNE:

- Alkhalili et al: 103 patients from New Mexico with either SHPT (34%) or THPT (66%) underwent parathyroidectomy and results of preoperative localization were retrospectively reviewed. The reported sensitivity for ectopic glands on a per-lesion basis by US was 32% [14].
- Andrade et al: 166 patients from Brazil with either SHPT (27%) or THPT (73%) underwent parathyroidectomy and results of preoperative localization were retrospectively reviewed. The reported sensitivity for ectopic glands on a per-lesion basis by US was 20% [13].
- Karipineni et al: This is the largest and most comprehensive study, a retrospective review of 2,975 patients from Maryland from 2004 to 2015. The aim of the study was to evaluate whether preoperative imaging could reliably identify ectopic glands in patients expected to have MGD. As such, the study was not limited to patients with SHPT but also included patients with THPT, lithium-induced PHPT, and PHPT due to multiple endocrine neoplasia; patients with SHPT comprised 55% of the cohort. On a per-lesion basis, exclusive of ectopic glands in the mediastinum (which were not included due to the assumption that US could not adequately image the mediastinum), the reported sensitivity of US in detecting ectopic glands was 7% [110].

Venous Sampling Parathyroid. There is no relevant literature regarding the use of venous sampling in the evaluation of SHPT.

Variant 4: Adult or child. Tertiary hyperparathyroidism. Initial imaging

All patients undergoing imaging in the setting of THPT should have biochemically proven disease, as imaging has no role in confirming or excluding the diagnosis [11]. As such, assessing the imaging test specificity and negative predictive value is not clinically relevant. THPT is typically a disorder of MGD in which the role of initial imaging is to accurately identify all eutopic and potential ectopic or supernumerary glands in an attempt to guide the surgical approach [12-14]; accordingly, these criteria focus on imaging test sensitivity and PPV.

It is possible that multiple imaging modalities may be utilized in combination during the initial imaging evaluation of THPT in an attempt to maximize the accuracy and confidence of parathyroid via concordant imaging results.

This is inferred from data regarding PHPT [16-23] and SHPT [12] showing improved sensitivity and PPV in parathyroid lesion localization with a combination of examinations over each examination in isolation.

CT Neck. There is no relevant literature regarding the use of CT neck in the evaluation of THPT.

MRI Neck. There is no relevant literature regarding the use of MRI neck performed without IV contrast, with IV contrast, or without and with IV contrast in the evaluation of THPT.

Sestamibi Dual-Phase Scan Neck. There is no relevant literature regarding the use of planar sestamibi dual-phase scan neck in the evaluation of THPT.

Sestamibi Dual-Phase Scan With SPECT or SPECT/CT Neck. There are limited data regarding the use of sestamibi dual-phase scans with SPECT or SPECT/CT in the evaluation of THPT:

- Karipineni et al: This is the largest and most comprehensive study, a retrospective review of 2,975 patients from Maryland from 2004 to 2015. The aim of the study was to evaluate whether preoperative imaging could reliably identify ectopic glands in patients expected to have MGD. As such, the study was not limited to patients with THPT but also included patients with SHPT, lithium-induced PHPT, and PHPT due to multiple endocrine neoplasia; patients with THPT comprised 21% of the cohort. On a per-lesion basis, the reported sensitivity of sestamibi dual-phase scans with SPECT in detecting ectopic glands was 29% [110].

Sestamibi Scan and I-123 Thyroid Scan. There is no relevant literature regarding the use of planar sestamibi scan and I-123 thyroid scan in the evaluation of THPT.

Sestamibi Scan and I-123 Thyroid Scan With SPECT or SPECT/CT Neck. There is no relevant literature regarding the use of sestamibi scan and I-123 thyroid scan with SPECT or SPECT/CT in the evaluation of THPT.

Sestamibi Scan and Perchnetate Thyroid Scan. There is no relevant literature regarding the use of planar sestamibi scan and perchnetate thyroid scan in the evaluation of THPT.

Sestamibi Scan and Perchnetate Thyroid Scan With SPECT or SPECT/CT Neck. There is no relevant literature regarding the use of sestamibi scan and perchnetate thyroid scan with SPECT or SPECT/CT in the evaluation of THPT.

US Parathyroid. When utilized as an initial imaging study in THPT, US conveys additional benefits of concomitant

evaluation of the thyroid gland. There are limited data regarding the use of US in the evaluation of THPT:

- Alkhalili et al: 103 patients from New Mexico with either SHPT (34%) or THPT (66%) underwent parathyroidectomy and results of preoperative localization were retrospectively reviewed. The reported sensitivity for ectopic glands on a per-lesion basis by US was 32% [14].
- Andrade et al: 166 patients from Brazil with either SHPT (27%) or THPT (73%) underwent parathyroidectomy and results of preoperative localization were retrospectively reviewed. The reported sensitivity for ectopic glands on a per-lesion basis by US was 20% [13].
- Karipineni et al: This is the largest and most comprehensive study, a retrospective review of 2,975 patients from Maryland from 2004 to 2015. The aim of the study was to evaluate whether preoperative imaging could reliably identify ectopic glands in patients expected to have MGD. As such, the study was not limited to patients with SHPT but also included patients with THPT, lithium-induced PHPT, and PHPT due to multiple endocrine neoplasia; patients with SHPT comprised 55% of the cohort. On a per-lesion basis, exclusive of ectopic glands in the mediastinum (which were not included because of the assumption that US could not adequately image the mediastinum), the reported sensitivity of US in detecting ectopic glands was 7% [110].

Venous Sampling Parathyroid. Because of its invasive technique, selective parathyroid venous sampling is typically reserved for reoperative surgical candidates with recurrent or persistent PHPT after noninvasive examinations (eg, US, sestamibi, CT, etc) yield nonlocalizing, equivocal, or discordant results [96]. Otherwise, there are limited data regarding the use of selective venous sampling in the initial evaluation of THPT:

- Witteveen et al: 20 patients from The Netherlands underwent parathyroidectomy for hyperparathyroidism, including 8 patients with THPT, and results of selective parathyroid venous sampling were retrospectively reviewed. Across the entire cohort, the reported sensitivity was 75% [93].

SUMMARY OF RECOMMENDATIONS

- **Variant 1:** US parathyroid or CT neck without and with IV contrast or sestamibi dual-phase scan neck or sestamibi dual-phase scan with SPECT or SPECT/CT neck or sestamibi scan and I-123 thyroid scan or sestamibi scan and I-123 thyroid scan with SPECT or SPECT/CT neck or sestamibi scan and perchnetate thyroid scan or sestamibi scan and perchnetate

thyroid scan with SPECT or SPECT/CT neck is usually appropriate as the initial imaging of all patients with PHPT. These procedures are typically equivalent alternatives (ie, only 1 procedure will be ordered to provide the clinical information to effectively manage the patient's care), although they may be used in a complementary manner to maximize the accuracy and confidence of parathyroid localization via concordant imaging results.

■ **Variant 2:** US parathyroid or CT neck without and with IV contrast or sestamibi dual-phase scan neck or sestamibi dual-phase scan with SPECT or SPECT/CT neck or sestamibi scan and I-123 thyroid scan or sestamibi scan and I-123 thyroid scan with SPECT or SPECT/CT neck or sestamibi scan and pertechnetate thyroid scan or sestamibi scan and pertechnetate thyroid scan with SPECT or SPECT/CT neck is usually appropriate as the initial imaging of all patients with recurrent or persistent PHPT after parathyroid surgery. These procedures are typically equivalent alternatives (ie, only 1 procedure will be ordered to provide the clinical information to effectively manage the patient's care), although they may be used in a complementary manner to maximize the accuracy and confidence of parathyroid localization via concordant imaging results.

■ **Variant 3:** US parathyroid or CT neck without and with IV contrast or sestamibi dual-phase scan neck or sestamibi dual-phase scan with SPECT or SPECT/CT neck or sestamibi scan and I-123 thyroid scan with SPECT or SPECT/CT neck or sestamibi scan and pertechnetate thyroid scan with SPECT or SPECT/CT neck is usually appropriate as the initial imaging of all patients with secondary hyperparathyroidism. These procedures are typically equivalent alternatives (ie, only 1 procedure will be ordered to provide the clinical information to effectively manage the patient's care), although they may be used in a complementary manner to maximize the accuracy and confidence of parathyroid localization via concordant imaging results. The panel did not agree on recommending sestamibi scan and pertechnetate thyroid scan or sestamibi scan and I-123 thyroid scan for this clinical scenario. There is insufficient medical literature to conclude whether or not these patients would benefit from sestamibi scan and pertechnetate thyroid scan or sestamibi scan and I-123 thyroid scan. These procedures in this patient population are controversial but may be appropriate.

■ **Variant 4:** US parathyroid or CT neck without and with IV contrast or sestamibi dual-phase scan neck or

sestamibi dual-phase scan with SPECT or SPECT/CT neck or sestamibi scan and I-123 thyroid scan with SPECT or SPECT/CT neck or sestamibi scan and pertechnetate thyroid scan or sestamibi scan and pertechnetate thyroid scan with SPECT or SPECT/CT neck is usually appropriate as the initial imaging of all patients with THPT. These procedures are equivalent alternatives (ie, only 1 procedure will be ordered to provide the clinical information to effectively manage the patient's care), although they may be used in a complementary manner to maximize the accuracy and confidence of parathyroid localization via concordant imaging results. The panel did not agree on recommending sestamibi scan and I-123 thyroid scan for this clinical scenario. There is insufficient medical literature to conclude whether or not these patients would benefit from sestamibi scan and I-123 thyroid scan. This procedure in this patient population is controversial but may be appropriate.

SUPPORTING DOCUMENTS

The evidence table, literature search, and appendix for this topic are available at <https://acsearch.acr.org/list>. The appendix includes the strength of evidence assessment and the final rating round tabulations for each recommendation.

For additional information on the Appropriateness Criteria methodology and other supporting documents go to www.acr.org/ac.

RELATIVE RADIATION LEVEL INFORMATION

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, because of both organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared with those specified for adults (see [Table 2](#)). Additional information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria® Radiation Dose Assessment Introduction document [113].

REFERENCES

1. Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. *Lancet* 2018;391:168-78.
2. Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism. *JAMA Surg* 2016;151:959-68.
3. Yeh MW, Ituarte PH, Zhou HC, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. *J Clin Endocrinol Metab* 2013;98:1122-9.
4. Gracie D, Hussain SS. Use of minimally invasive parathyroidectomy techniques in sporadic primary hyperparathyroidism: systematic review. *J Laryngol Otol* 2012;126:221-7.
5. Kunstman JW, Udelsman R. Superiority of minimally invasive parathyroidectomy. *Adv Surg* 2012;46:171-89.
6. Laird AM, Libutti SK. Minimally invasive parathyroidectomy versus bilateral neck exploration for primary hyperparathyroidism. *Surg Oncol Clin N Am* 2016;25:103-18.
7. Mancilla EE, Levine MA, Adzick NS. Outcomes of minimally invasive parathyroidectomy in pediatric patients with primary hyperparathyroidism owing to parathyroid adenoma: a single institution experience. *J Pediatr Surg* 2017;52:188-91.
8. Zafereo M, Yu J, Angelos P, et al. American Head and Neck Society Endocrine Surgery Section update on parathyroid imaging for surgical candidates with primary hyperparathyroidism. *Head Neck* 2019;41:2398-409.
9. Joliat GR, Demartines N, Portmann L, Boubaker A, Matter M. Successful minimally invasive surgery for primary hyperparathyroidism: influence of preoperative imaging and intraoperative parathyroid hormone levels. *Langenbecks Arch Surg* 2015;400:937-44.
10. Stack BC Jr, Tolley NS, Bartel TB, et al. AHNS Series: Do you know your guidelines? Optimizing outcomes in reoperative parathyroid surgery: definitive multidisciplinary joint consensus guidelines of the American Head and Neck Society and the British Association of Endocrine and Thyroid Surgeons. *Head Neck* 2018;40:1617-29.
11. Fraser WD. Hyperparathyroidism. *Lancet* 2009;374:145-58.
12. Vulpio C, Bossola M, De Gaetano A, et al. Usefulness of the combination of ultrasonography and 99mTc-sestamibi scintigraphy in the preoperative evaluation of uremic secondary hyperparathyroidism. *Head Neck* 2010;32:1226-35.
13. Andrade JS, Mangussi-Gomes JP, Rocha LA, et al. Localization of ectopic and supernumerary parathyroid glands in patients with secondary and tertiary hyperparathyroidism: surgical description and correlation with preoperative ultrasonography and Tc99m-Sestamibi scintigraphy. *Braz J Otorhinolaryngol* 2014;80:29-34.
14. Alkhalili E, Tasci Y, Aksoy E, et al. The utility of neck ultrasound and sestamibi scans in patients with secondary and tertiary hyperparathyroidism. *World J Surg* 2015;39:701-5.
15. Hindie E, Ugur O, Fuster D, et al. 2009 EANM parathyroid guidelines. *Eur J Nucl Med Mol Imaging* 2009;36:1201-16.
16. Christakis I, Vu T, Chuang HH, et al. The diagnostic accuracy of neck ultrasound, 4D-Computed tomography and sestamibi imaging in parathyroid carcinoma. *Eur J Radiol* 2017;95:82-8.
17. Frank E, Ale-Salvo D, Park J, Liu Y, Simental A Jr, Inman JC. Preoperative imaging for parathyroid localization in patients with concurrent thyroid disease: a systematic review. *Head Neck* 2018;40:1577-87.
18. Kedarisetty S, Fundakowski C, Ramakrishnan K, Dadparvar S. Clinical value of Tc99m-MIBI SPECT/CT versus 4D-CT or US in management of patients with hyperparathyroidism. *Ear Nose Throat J* 2019;98:149-57.
19. Kutler DI, Moquete R, Kazam E, Kuhel WI. Parathyroid localization with modified 4D-computed tomography and ultrasonography for patients with primary hyperparathyroidism. *Laryngoscope* 2011;121:1219-24.
20. Patel CN, Salahudeen HM, Lansdown M, Scarsbrook AF. Clinical utility of ultrasound and 99mTc sestamibi SPECT/CT for preoperative localization of parathyroid adenoma in patients with primary hyperparathyroidism. *Clin Radiol* 2010;65:278-87.
21. Scattergood S, Marsden M, Kyrimi E, Ishii H, Doddi S, Sinha P. Combined ultrasound and Sestamibi scintigraphy provides accurate preoperative localisation for patients with primary hyperparathyroidism. *Ann R Coll Surg Engl* 2019;101:97-102.
22. Tee MC, Chan SK, Nguyen V, et al. Incremental value and clinical impact of neck sonography for primary hyperparathyroidism: a risk-adjusted analysis. *Can J Surg* 2013;56:325-31.
23. Touska P, Elstob A, Rao N, Parthipun A. SPECT/CT-guided ultrasound for parathyroid adenoma localization: a 1-stop approach. *J Nucl Med Technol* 2019;47:64-9.
24. Kuzminski SJ, Sosa JA, Hoang JK. Update in parathyroid imaging. *Magn Reson Imaging Clin N Am* 2018;26:151-66.
25. Sandqvist P, Nilsson IL, Gryback P, Sanchez-Crespo A, Sundin A. Multiphase iodine contrast-enhanced SPECT/CT outperforms non-enhanced SPECT/CT for preoperative localization of small parathyroid adenomas. *Clin Nucl Med* 2019;44:929-35.
26. Rodgers SE, Hunter GJ, Hamberg LM, et al. Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography. *Surgery* 2006;140:932-40; discussion 40-1.
27. Campbell MJ, Sicuro P, Alseidi A, Blackmore CC, Ryan JA Jr. Two-phase (low-dose) computed tomography is as effective as 4D-CT for identifying enlarged parathyroid glands. *Int J Surg* 2015;14:80-4.
28. Hunter GJ, Ginat DT, Kelly HR, Halpern EF, Hamberg LM. Discriminating parathyroid adenoma from local mimics by using inherent tissue attenuation and vascular information obtained with four-dimensional CT: formulation of a multinomial logistic regression model. *Radiology* 2014;270:168-75.
29. Kelly HR, Hamberg LM, Hunter GJ. 4D-CT for preoperative localization of abnormal parathyroid glands in patients with hyperparathyroidism: accuracy and ability to stratify patients by unilateral versus bilateral disease in surgery-naïve and re-exploration patients. *AJNR Am J Neuroradiol* 2014;35:176-81.
30. Bahl M, Sepahdari AR, Sosa JA, Hoang JK. Parathyroid adenomas and hyperplasia on four-dimensional CT scans: three patterns of enhancement relative to the thyroid gland justify a three-phase protocol. *Radiology* 2015;277:454-62.
31. Bahl M. Preoperative parathyroid imaging: trends in utilization and comparative accuracy of sonography, scintigraphy, and 4-dimensional computed tomography. *J Comput Assist Tomogr* 2019;43:264-8.
32. Yeh R, Tay YD, Tabacco G, et al. Diagnostic performance of 4D CT and sestamibi SPECT/CT in localizing parathyroid adenomas in primary hyperparathyroidism. *Radiology* 2019;291:469-76.
33. Sho S, Yuen AD, Yeh MW, Livhits MJ, Sepahdari AR. Factors associated with discordance between preoperative parathyroid 4-dimensional computed tomographic scans and intraoperative findings during parathyroidectomy. *JAMA Surg* 2017;152:1141-7.
34. Hoang JK, Williams K, Gaillard F, Dixon A, Sosa JA. Parathyroid 4D-CT: multi-institutional international survey of use and trends. *Otolaryngol Head Neck Surg* 2016;155:956-60.
35. Eichhorn-Wharry LI, Carlin AM, Talpos GB. Mild hypercalcemia: an indication to select 4-dimensional computed tomography scan for preoperative localization of parathyroid adenomas. *Am J Surg* 2011;201:334-8; discussion 38.
36. Brown SJ, Lee JC, Christie J, et al. Four-dimensional computed tomography for parathyroid localization: a new imaging modality. *ANZ J Surg* 2015;85:483-7.
37. Starker LF, Mahajan A, Bjorklund P, Sze G, Udelsman R, Carling T. 4D parathyroid CT as the initial localization study for patients with de novo primary hyperparathyroidism. *Ann Surg Oncol* 2011;18:1723-8.
38. Suh YJ, Choi JY, Kim SJ, et al. Comparison of 4D CT, ultrasonography, and 99mTc sestamibi SPECT/CT in localizing single-gland primary hyperparathyroidism. *Otolaryngol Head Neck Surg* 2015;152:438-43.
39. Chazen JL, Gupta A, Dunning A, Phillips CD. Diagnostic accuracy of 4D-CT for parathyroid adenomas and hyperplasia. *AJNR Am J Neuroradiol* 2012;33:429-33.

40. Tian Y, Tanny ST, Einsiedel P, et al. Four-dimensional computed tomography: clinical impact for patients with primary hyperparathyroidism. *Ann Surg Oncol* 2018;25:117-21.
41. Leiva-Salinas C, Flors L, Durst CR, et al. Detection of parathyroid adenomas using a monophasic dual-energy computed tomography acquisition: diagnostic performance and potential radiation dose reduction. *Neuroradiology* 2016;58:1135-41.
42. Linda DD, Ng B, Rebello R, Harish S, Ioannidis G, Young JE. The utility of multidetector computed tomography for detection of parathyroid disease in the setting of primary hyperparathyroidism. *Can Assoc Radiol J* 2012;63:100-8.
43. Silver E, Sadeghi N, Knoll S, Taheri MR. Utility of single-phase computed tomography in identifying parathyroid adenomas: a feasibility study. *Curr Probl Diagn Radiol* 2018;47:90-3.
44. Griffith B, Chaudhary H, Mahmood G, et al. Accuracy of 2-phase parathyroid CT for the preoperative localization of parathyroid adenomas in primary hyperparathyroidism. *AJNR Am J Neuroradiol* 2015;36:2373-9.
45. Krakauer M, Wieslander B, Myschetzky PS, et al. A prospective comparative study of parathyroid dual-phase scintigraphy, dual-isotope subtraction scintigraphy, 4D-CT, and Ultrasonography in primary hyperparathyroidism. *Clin Nucl Med* 2016;41:93-100.
46. Agha A, Hornung M, Rennert J, et al. Contrast-enhanced ultrasonography for localization of pathologic glands in patients with primary hyperparathyroidism. *Surgery* 2012;151:580-6.
47. Akbaba G, Berker D, Isik S, et al. A comparative study of preoperative imaging methods in patients with primary hyperparathyroidism: ultrasonography, 99mTc sestamibi, single photon emission computed tomography, and magnetic resonance imaging. *J Endocrinol Invest* 2012;35:359-64.
48. Kluijfhout WP, Venkatesh S, Beninato T, et al. Performance of magnetic resonance imaging in the evaluation of first-time and reoperative primary hyperparathyroidism. *Surgery* 2016;160:747-54.
49. Grayev AM, Gentry LR, Hartman MJ, Chen H, Perlman SB, Reeder SB. Presurgical localization of parathyroid adenomas with magnetic resonance imaging at 3.0 T: an adjunct method to supplement traditional imaging. *Ann Surg Oncol* 2012;19:981-9.
50. Argiro R, Diacinti D, Sacconi B, et al. Diagnostic accuracy of 3T magnetic resonance imaging in the preoperative localisation of parathyroid adenomas: comparison with ultrasound and 99mTc-sestamibi scans. *Eur Radiol* 2018;28:4900-8.
51. Becker JL, Patel V, Johnson KJ, et al. 4D-dynamic contrast-enhanced MRI for preoperative localization in patients with primary hyperparathyroidism. *AJNR Am J Neuroradiol* 2020;41:522-8.
52. Cakal E, Cakir E, Dilli A, et al. Parathyroid adenoma screening efficacies of different imaging tools and factors affecting the success rates. *Clin Imaging* 2012;36:688-94.
53. Adkisson CD, Koonce SL, Heckman MG, Thomas CS, Harris AS, Casler JD. Predictors of accuracy in preoperative parathyroid adenoma localization using ultrasound and Tc-99m-Sestamibi: a 4-quadrant analysis. *Am J Otolaryngol* 2013;34:508-16.
54. Caveny SA, Klingensmith WC 3rd, Martin WE, et al. Parathyroid imaging: the importance of dual-radiopharmaceutical simultaneous acquisition with 99mTc-sestamibi and 123I. *J Nucl Med Technol* 2012;40:104-10.
55. Cho NL, Gawande AA, Sheu EG, Moore FD Jr, Ruan DT. Critical role of identification of the second gland during unilateral parathyroid surgery: a prospective review of 119 patients with concordant localization. *Arch Surg* 2011;146:512-6.
56. Glynn N, Lynn N, Donagh C, et al. The utility of 99mTc-sestamibi scintigraphy in the localisation of parathyroid adenomas in primary hyperparathyroidism. *Ir J Med Sci* 2011;180:191-4.
57. Kim D, Rhodes JA, Hashim JA, et al. Highly specific preoperative selection of solitary parathyroid adenoma cases in primary hyperparathyroidism by quantitative image analysis of the early-phase technetium-99m sestamibi scan. *J Med Imaging Radiat Oncol* 2018;62:642-8.
58. Medas F, Erdas E, Longheu A, et al. Retrospective evaluation of the pre- and postoperative factors influencing the sensitivity of localization studies in primary hyperparathyroidism. *Int J Surg* 2016;25:82-7.
59. Raruenrom Y, Theerakulpisut D, Wongsurawat N, Somboonporn C. Diagnostic accuracy of planar, SPECT, and SPECT/CT parathyroid scintigraphy protocols in patients with hyperparathyroidism. *Nucl Med Rev Cent East Eur* 2018;21:20-5.
60. Smith RB, Evasovich M, Girod DA, et al. Ultrasound for localization in primary hyperparathyroidism. *Otolaryngol Head Neck Surg* 2013;149:366-71.
61. Thomas DL, Bartel T, Menda Y, Howe J, Graham MM, Juweid ME. Single photon emission computed tomography (SPECT) should be routinely performed for the detection of parathyroid abnormalities utilizing technetium-99m sestamibi parathyroid scintigraphy. *Clin Nucl Med* 2009;34:651-5.
62. Wong KK, Fig LM, Gross MD, Dwamena BA. Parathyroid adenoma localization with 99mTc-sestamibi SPECT/CT: a meta-analysis. *Nucl Med Commun* 2015;36:363-75.
63. Xue J, Liu Y, Ji T, et al. Comparison between technetium-99m methoxyisobutylisonitrile scintigraphy and ultrasound in the diagnosis of parathyroid adenoma and parathyroid hyperplasia. *Nucl Med Commun* 2018;39:1129-37.
64. Bahador FM, Latifi HR, Grossman SJ, Oza UD, Xu H, Griffith LK. Optimal interpretative strategy for preoperative parathyroid scintigraphy. *Clin Nucl Med* 2015;40:116-22.
65. Leslie WD, Dupont JO, Bybel B, Riese KT. Parathyroid 99mTc-sestamibi scintigraphy: dual-tracer subtraction is superior to double-phase washout. *Eur J Nucl Med Mol Imaging* 2002;29:1566-70.
66. Gomez-Ramirez J, Sancho-Insenser JJ, Pereira JA, Jimeno J, Munne A, Sitges-Serra A. Impact of thyroid nodular disease on 99mTc-sestamibi scintigraphy in patients with primary hyperparathyroidism. *Langenbecks Arch Surg* 2010;395:929-33.
67. Alagaratnam S, Brain C, Spoudeas H, et al. Surgical treatment of children with hyperparathyroidism: single centre experience. *J Pediatr Surg* 2014;49:1539-43.
68. Greenspan BS, Dillehay G, Intenzo C, et al. SNM practice guideline for parathyroid scintigraphy 4.0. 2012;40:111-118.
69. Eslamy HK, Ziessman HA. Parathyroid scintigraphy in patients with primary hyperparathyroidism: 99mTc sestamibi SPECT and SPECT/CT. *Radiographics* 2008;28:1461-76.
70. Cheung K, Wang TS, Farrokhfar F, Roman SA, Sosa JA. A meta-analysis of preoperative localization techniques for patients with primary hyperparathyroidism. *Ann Surg Oncol* 2012;19:577-83.
71. Galvin L, Oldan JD, Bahl M, Eastwood JD, Sosa JA, Hoang JK. Parathyroid 4D CT and scintigraphy: what factors contribute to missed parathyroid lesions? *Otolaryngol Head Neck Surg* 2016;154:847-53.
72. Swanson TW, Chan SK, Jones SJ, et al. Determinants of Tc-99m sestamibi SPECT scan sensitivity in primary hyperparathyroidism. *Am J Surg* 2010;199:614-20.
73. Nichols KJ, Tronco GG, Palestro CJ. Influence of multigland parathyroid disease on 99mTc-sestamibi SPECT/CT. *Clin Nucl Med* 2016;41:282-8.
74. Bhatt PR, Klingensmith WC 3rd, Bagrosky BM, et al. Parathyroid imaging with simultaneous acquisition of 99mTc-sestamibi and 123I: the relative merits of pinhole collimation and SPECT/CT. *J Nucl Med Technol* 2015;43:275-81.
75. Hassler S, Ben-Sellem D, Hubele F, Constantinesco A, Goetz C. Dual-isotope 99mTc-MIBI/123I parathyroid scintigraphy in primary hyperparathyroidism: comparison of subtraction SPECT/CT and pinhole planar scan. *Clin Nucl Med* 2014;39:32-6.
76. Lee GS, McKenzie TJ, Mullan BP, Farley DR, Thompson GB, Richards ML. A multimodal imaging protocol, (123I)/(99mTc)-sestamibi, SPECT, and SPECT/CT, in primary hyperparathyroidism adds limited benefit for preoperative localization. *World J Surg* 2016;40:589-94.

77. Dy BM, Richards ML, Vazquez BJ, Thompson GB, Farley DR, Grant CS. Primary hyperparathyroidism and negative Tc99 sestamibi imaging: to operate or not? *Ann Surg Oncol* 2012;19:2272-8.
78. Guerin C, Lowery A, Gabriel S, et al. Preoperative imaging for focused parathyroidectomy: making a good strategy even better. *Eur J Endocrinol* 2015;172:519-26.
79. Woods AM, Bolster AA, Han S, et al. Dual-isotope subtraction SPECT-CT in parathyroid localization. *Nucl Med Commun* 2017;38:1047-54.
80. Keane DF, Roberts G, Smith R, et al. Planar parathyroid localization scintigraphy: a comparison of subtraction and 1-, 2- and 3-h washout protocols. *Nucl Med Commun* 2013;34:582-9.
81. Powell DK, Nwoke F, Goldfarb RC, Ongseng F. Tc-99m sestamibi parathyroid gland scintigraphy: added value of Tc-99m pertechnetate thyroid imaging for increasing interpretation confidence and avoiding additional testing. *Clin Imaging* 2013;37:475-9.
82. Berner AM, Haroon A, Nowosinska E, et al. Localization of parathyroid disease with "sequential multiphase and dual-tracer" technique and comparison with neck ultrasound. *Nucl Med Commun* 2015;36:45-52.
83. Huang Z, Lou C. (99m)TcO4(-)/(99m)Tc-MIBI dual-tracer scintigraphy for preoperative localization of parathyroid adenomas. *J Int Med Res* 2019;47:836-45.
84. Pata G, Casella C, Besuzio S, Mittemperger F, Salerni B. Clinical appraisal of 99m technetium-sestamibi SPECT/CT compared to conventional SPECT in patients with primary hyperparathyroidism and concomitant nodular goiter. *Thyroid* 2010;20:1121-7.
85. Nafisi Moghadam R, Amlshahbaz AP, Namiranian N, et al. Comparative diagnostic performance of ultrasonography and 99mTc-sestamibi scintigraphy for parathyroid adenoma in primary hyperparathyroidism; systematic review and meta-analysis. *Asian Pac J Cancer Prev* 2017;18:3195-200.
86. Stern S, Tzelnick S, Mizrahi A, Cohen M, Shpitzer T, Bachar G. Accuracy of neck ultrasonography in predicting the size and location of parathyroid adenomas. *Otolaryngol Head Neck Surg* 2018;159:968-72.
87. Untch BR, Adam MA, Scheri RP, et al. Surgeon-performed ultrasound is superior to 99Tc-sestamibi scanning to localize parathyroid adenomas in patients with primary hyperparathyroidism: results in 516 patients over 10 years. *J Am Coll Surg* 2011;212:522-9; discussion 29-31.
88. Butt HZ, Husainy MA, Bolia A, London NJ. Ultrasonography alone can reliably locate parathyroid tumours and facilitates minimally invasive parathyroidectomy. *Ann R Coll Surg Engl* 2015;97:420-4.
89. Tresoldi S, Pompili G, Maiolino R, et al. Primary hyperparathyroidism: can ultrasonography be the only preoperative diagnostic procedure? *Radiol Med* 2009;114:1159-72.
90. Beland MD, Mayo-Smith WW, Grand DJ, Machan JT, Monchik JM. Dynamic MDCT for localization of occult parathyroid adenomas in 26 patients with primary hyperparathyroidism. *AJR Am J Roentgenol* 2011;196:61-5.
91. Erbil Y, Barbaros U, Yanik BT, et al. Impact of gland morphology and concomitant thyroid nodules on preoperative localization of parathyroid adenomas. *Laryngoscope* 2006;116:580-5.
92. Hader C, Uder M, Loose RW, Linnemann U, Bertsch T, Adamus R. Selective venous blood sampling for hyperparathyroidism with unclear localization of the parathyroid gland. *Rofo* 2016;188:1144-50.
93. Witteveen JE, Kievit J, van Erkel AR, Morreau H, Romijn JA, Hamdy NA. The role of selective venous sampling in the management of persistent hyperparathyroidism revisited. *Eur J Endocrinol* 2010;163:945-52.
94. Alvarado R, Meyer-Rochow G, Sywak M, Delbridge L, Sidhu S. Bilateral internal jugular venous sampling for parathyroid hormone determination in patients with nonlocalizing primary hyperparathyroidism. *World J Surg* 2010;34:1299-303.
95. Carneiro-Pla D. Effectiveness of "office"-based, ultrasound-guided differential jugular venous sampling (DJVS) of parathormone in patients with primary hyperparathyroidism. *Surgery* 2009;146:1014-20.
96. Bunch PM, Kelly HR. Preoperative imaging techniques in primary hyperparathyroidism: a review. *JAMA Otolaryngol Head Neck Surg* 2018;144:929-37.
97. Ginsburg M, Christoforidis GA, Zivin SP, et al. Adenoma localization for recurrent or persistent primary hyperparathyroidism using dynamic four-dimensional CT and venous sampling. *J Vasc Interv Radiol* 2015;26:79-86.
98. Aschenbach R, Tuda S, Lamster E, et al. Dynamic magnetic resonance angiography for localization of hyperfunctioning parathyroid glands in the reoperative neck. *Eur J Radiol* 2012;81:3371-7.
99. Witteveen JE, Kievit J, Stokkel MP, Morreau H, Romijn JA, Hamdy NA. Limitations of Tc99m-MIBI-SPECT imaging scans in persistent primary hyperparathyroidism. *World J Surg* 2011;35:128-39.
100. Shin JJ, Milas M, Mitchell J, Berber E, Ross L, Siperstein A. Impact of localization studies and clinical scenario in patients with hyperparathyroidism being evaluated for reoperative neck surgery. *Arch Surg* 2011;146:1397-403.
101. Hamidi M, Sullivan M, Hunter G, et al. 4D-CT is superior to ultrasound and sestamibi for localizing recurrent parathyroid disease. *Ann Surg Oncol* 2018;25:1403-9.
102. Mihai R, Simon D, Hellman P. Imaging for primary hyperparathyroidism—an evidence-based analysis. *Langenbecks Arch Surg* 2009;394:765-84.
103. Schalin-Jantti C, Ryhanen E, Heiskanen I, et al. Planar scintigraphy with 123I/99mTc-sestamibi, 99mTc-sestamibi SPECT/CT, 11C-methionine PET/CT, or selective venous sampling before reoperation of primary hyperparathyroidism? *J Nucl Med* 2013;54:739-47.
104. Lebastchi AH, Aruny JE, Donovan PI, et al. Real-time super selective venous sampling in remedial parathyroid surgery. *J Am Coll Surg* 2015;220:994-1000.
105. Sun PY, Thompson SM, Andrews JC, et al. Selective parathyroid hormone venous sampling in patients with persistent or recurrent primary hyperparathyroidism and negative, equivocal or discordant noninvasive imaging. *World J Surg* 2016;40:2956-63.
106. Lee JB, Kim WY, Lee YM. The role of preoperative ultrasonography, computed tomography, and sestamibi scintigraphy localization in secondary hyperparathyroidism. *Ann Surg Treat Res* 2015;89:300-5.
107. Hiramitsu T, Tomosugi T, Okada M, et al. Pre-operative localisation of the parathyroid glands in secondary hyperparathyroidism: a retrospective cohort study. *Sci Rep* 2019;9:14634.
108. Yang J, Hao R, Yuan L, Li C, Yan J, Zhen L. Value of dual-phase (99m)Tc-sestamibi scintigraphy with neck and thoracic SPECT/CT in secondary hyperparathyroidism. *AJR Am J Roentgenol* 2014;202:180-4.
109. Li P, Liu Q, Tang D, et al. Lesion based diagnostic performance of dual phase (99m)Tc-MIBI SPECT/CT imaging and ultrasonography in patients with secondary hyperparathyroidism. *BMC Med Imaging* 2017;17:60.
110. Karipineni F, Sahli Z, Somervell H, et al. Are preoperative sestamibi scans useful for identifying ectopic parathyroid glands in patients with expected multigland parathyroid disease? *Surgery* 2018;163:35-41.
111. Meola M, Petrucci I, Calliada F, et al. Presurgical setting of secondary hyperparathyroidism using high-resolution sonography and color Doppler. *Ultraschall Med* 2011;32(Suppl 1):S74-82.
112. Kawata R, Kotetsu L, Takamaki A, Yoshimura K, Takenaka H. Ultrasonography for preoperative localization of enlarged parathyroid glands in secondary hyperparathyroidism. *Auris Nasus Larynx* 2009;36:461-5.
113. American College of Radiology. ACR Appropriateness Criteria[®] radiation dose assessment introduction Available at: <https://www.acr.org/-/media/ACR/Files/Appropriateness-Criteria/RadiationDoseAssessmentIntro.pdf>. Accessed March 26, 2021.